{"id":283,"date":"2025-08-06T10:00:00","date_gmt":"2025-08-06T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=283"},"modified":"2025-09-10T06:23:49","modified_gmt":"2025-09-10T06:23:49","slug":"technology-collaboration-xtalpi-and-dovetree-enters-a-6-billion-usd-collaboration-on-ai-drug-discovery","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/283.html","title":{"rendered":"[Technology Collaboration] XtalPi and Dovetree enters a 6 billion USD Collaboration on AI drug discovery"},"content":{"rendered":"\n<p>Announced Date: 2025-08-05 (August 5, 2025) <\/p>\n\n\n\n<p>Licensor: XtalPi Inc. (China)<\/p>\n\n\n\n<p>Licensee: DoveTree Medicines\uff08US\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Collaboration:<\/p>\n\n\n\n<p>Under the agreement, XtalPi will leverage its end-to-end AI drug discovery platform integrating artificial intelligence and robotics to discover and develop small molecule and antibody drug candidates against multiple targets selected by Dovetree. <\/p>\n\n\n\n<p>These targets will primarily focus on oncology, autoimmune diseases, central nervous system (CNS) disorders, and metabolic diseases.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of $51 million, further payment of $49 million,  <\/p>\n\n\n\n<p>Development, regulatory and commercial milestone payments totaling up to $5.89 billion, <\/p>\n\n\n\n<p>Tiered royalties in the mid-single-digit percentage range based on the annual net sales of resulting products.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/xtalpi-and-dovetree-announce-landmark-6-billion-ai-drug-discovery-collaboration-302523824.html\">XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration (prnewswire.com)<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of  XtalPi, \u6676\u6cf0<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-08-05 (August 5, 2025) Licensor: XtalPi Inc. (China) Licensee: DoveTree Medicines\uff08US\uff09 . Scope of &hellip; <a title=\"[Technology Collaboration] XtalPi and Dovetree enters a 6 billion USD Collaboration on AI drug discovery\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/283.html\"><span class=\"screen-reader-text\">[Technology Collaboration] XtalPi and Dovetree enters a 6 billion USD Collaboration on AI drug discovery<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-283","post","type-post","status-publish","format-standard","hentry","category-china-tech-corp"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=283"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/283\/revisions"}],"predecessor-version":[{"id":285,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/283\/revisions\/285"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}